Due to chromosome arm LOH at 8p22 during the early development of CRC, a patient heterozygous for a rapid and a slow NAT2 allele may lose the rapid variant in the tumor cells, effectively rendering them deficient in NAT2 activity and sensitive to a cytotoxic substrate of NAT211. Here, NAT2 is linked to neoplasm.